Investigating how MIZ1 affects breast cancer outcomes in African American women
Official title: MIZ1 Activation in Triple-negative Breast Cancer Racial Disparities
Funded at Case Western Reserve University · NIH-11010395 · Data updated 2026-11-12
This study is looking at why African American women with triple-negative breast cancer may have different outcomes compared to European American women, focusing on a specific factor called MIZ1 that seems to affect survival rates, with the hope of finding better treatment options for those affected.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Case Western Reserve University NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project start | February 1, 2024 |
| Project end | January 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $617,723 |
| NIH project number | 5R01CA275910-02 |
| Project ID | NIH-11010395 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are African American women diagnosed with triple-negative breast cancer.
✕Less likely to help
Patients who do not have triple-negative breast cancer or are not of African American descent may not benefit from this research.
What this research studies
This research focuses on understanding the differences in triple-negative breast cancer (TNBC) outcomes between African American (AA) women and their European American counterparts. It aims to explore the role of MIZ1 activation in TNBC, which has been found to occur more frequently in AA tumors and is linked to poorer survival rates. By analyzing tumor samples from multiple patient cohorts, the study seeks to uncover the biological mechanisms behind these disparities and identify potential new treatment strategies targeting MIZ1 signaling. The ultimate goal is to improve clinical outcomes for AA women suffering from TNBC.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for triple-negative breast cancer specifically tailored for African American women.
How similar studies have gone: Other research has shown promising results in understanding racial disparities in cancer outcomes, making this approach both relevant and potentially impactful.
Where this research is happening
-
Case Western Reserve University
Cleveland, United States Active
Researchers
- Principal investigator: Schiemann, William — Case Western Reserve University
- Study coordinator: Schiemann, William
Related research
Other NIH-funded projects on the same topics.
-
Genomic study to understand how genetics and epigenetics shape triple-negative breast cancer in African ancestry
This study looks at how inherited genes and gene activity affect triple-negative breast cancer in people of African ancestry to better understand why outcomes can be worse.
-
Co-Targeting IL-6 and CDK4/6 to Prevent TNBC in Women Veterans
A study aims to block two cancer-promoting pathways (IL-6 and CDK4/6) to prevent or reduce progression of triple-negative breast cancer in women veterans.
-
Linking heavy metal exposure to a tougher breast cancer type (TNBC)
Aimed at understanding how heavy metals like cadmium might trigger a dangerous breast cancer type (TNBC) in people, especially those with BRCA1 risk, to identify possible future treatment strategies.
-
Dormancy in Triple-Negative Breast Cancer: How Liver and Skin Metastases Go Quiet or Reactivate
Researchers will study how dormant cancer cells in liver and skin metastases of triple-negative breast cancer become quiescent or wake up, using organ-on-chip models and single-cell analysis to map chromatin states.
-
Rac-enhanced CAR-Macrophages against TNBC
A new cell therapy approach uses engineered macrophages with a CAR and Rac2 activation to target and kill triple-negative breast cancer cells expressing CSPG4.
-
A new peptide therapy to help treat metastatic triple-negative breast cancer
A new peptide therapy called PEG-FUD is being tested to help treat metastatic triple-negative breast cancer by normalizing the tumor environment to improve treatment delivery.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.